Gene:
ERCC3
excision repair cross-complementing rodent repair deficiency, complementation group 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all ERCC3 variant annotations

Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs3738948 128018063A>G, 17766726A>G, 2064+741T>C, 38690T>C
A > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142

Overview

Alternate Names:  excision repair cross-complementing rodent repair deficiency, complementation group 3; xeroderma pigmentosum group B complementing
Alternate Symbols:  BTF2; GTF2H; RAD25; TFIIH; XPB
PharmGKB Accession Id: PA27849

Details

Cytogenetic Location: chr2 : q14.3 - q14.3
GP mRNA Boundary: chr2 : 128014866 - 128051752
GP Gene Boundary: chr2 : 128011866 - 128061752
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Dual incision reaction in GG-NER - (Reactome via Pathway Interaction Database)
  2. Dual incision reaction in TC-NER - (Reactome via Pathway Interaction Database)
  3. Formation of HIV-1 elongation complex containing HIV-1 Tat - (Reactome via Pathway Interaction Database)
  4. Formation of incision complex in GG-NER - (Reactome via Pathway Interaction Database)
  5. Formation of RNA Pol II elongation complex - (Reactome via Pathway Interaction Database)
  6. Formation of the Early Elongation Complex - (Reactome via Pathway Interaction Database)
  7. Formation of the HIV-1 Early Elongation Complex - (Reactome via Pathway Interaction Database)
  8. Formation of transcription-coupled NER (TC-NER) repair complex - (Reactome via Pathway Interaction Database)
  9. HIV-1 Transcription Initiation - (Reactome via Pathway Interaction Database)
  10. HIV-1 Transcription Pre-Initiation - (Reactome via Pathway Interaction Database)
  11. mRNA Capping - (Reactome via Pathway Interaction Database)
  12. RNA Pol II CTD phosphorylation and interaction with CE - (Reactome via Pathway Interaction Database)
  13. RNA Pol II CTD phosphorylation and interaction with CE - (Reactome via Pathway Interaction Database)
  14. RNA Polymerase I Chain Elongation - (Reactome via Pathway Interaction Database)
  15. RNA Polymerase I Promoter Escape - (Reactome via Pathway Interaction Database)
  16. RNA Polymerase I Transcription Initiation - (Reactome via Pathway Interaction Database)
  17. RNA Polymerase I Transcription Termination - (Reactome via Pathway Interaction Database)
  18. RNA Polymerase II HIV-1 Promoter Escape - (Reactome via Pathway Interaction Database)
  19. RNA Polymerase II Promoter Escape - (Reactome via Pathway Interaction Database)
  20. RNA Polymerase II Transcription - (Reactome via Pathway Interaction Database)
  21. RNA Polymerase II Transcription Elongation - (Reactome via Pathway Interaction Database)
  22. RNA Polymerase II Transcription Initiation - (Reactome via Pathway Interaction Database)
  23. RNA Polymerase II Transcription Initiation And Promoter Clearance - (Reactome via Pathway Interaction Database)
  24. RNA Polymerase II Transcription Pre-Initiation - (Reactome via Pathway Interaction Database)
  25. Tat-mediated elongation of the HIV-1 transcript - (Reactome via Pathway Interaction Database)
  26. Transcription of the HIV genome - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Platinum compounds

Curated Information ?

Publications related to ERCC3: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer letters. 2014. Sullivan Ivana, et al. PubMed

LinkOuts

Entrez Gene:
2071
OMIM:
133510
601675
610651
UCSC Genome Browser:
NM_000122
RefSeq RNA:
NM_000122
RefSeq Protein:
NP_000113
RefSeq DNA:
AC_000045
AC_000134
NC_000002
NG_007454
NT_022135
NW_001838849
NW_921507
UniProtKB:
ERCC3_HUMAN (P19447)
Ensembl:
ENSG00000163161
GenAtlas:
ERCC3
GeneCard:
ERCC3
MutDB:
ERCC3
ALFRED:
LO012779A
HuGE:
ERCC3
Comparative Toxicogenomics Database:
2071
ModBase:
P19447
HumanCyc Gene:
HS08797
HGNC:
3435

Common Searches